Announced Thu, 9 Jul · 10:53 IST
Piramal Pharma's US Sellersville facility clears US FDA inspection
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+5.1%1-day move
₹168.00
prior close
₹171.40
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.8+1.7+2.0+1.1+5.1+3.5+2.3+2.1+4.5+6.8————
Up moveDown movePending
AI summary
US FDA has issued an Establishment Inspection Report (EIR) and successfully closed the inspection at Piramal Pharma's Sellersville (USA) manufacturing facility, the company informed exchanges on July 9, 2026. This follows an earlier intimation dated May 10, 2026. No adverse observations were reported, indicating a clean inspection outcome for the US facility.
Likely market impact
Positive - clean US FDA clearance reduces compliance risk and supports uninterrupted supply from the US facility.